Response to Comment on Itoh et al. Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study. Diabetes Care 2018;41:1275–1284

  • Hiroshi Itoh
    Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, Tokyo, Japan
  • Kenji Ueshima
    Department of EBM Research, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan
  • Issei Komuro
    Department of Cardiovascular Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

Description

We thank Donzelli et al. (1) for their interest in our article (2). The report of the EMPATHY study (2) showed no significant difference between the intensive group and the standard group for the primary end point, but the difference was significant for cerebral events, which was one of the secondary end points. Our study did not adjust for multiplicity of secondary end points. We thus agree with the authors of the letter (1) that these results do not provide substantial evidence that aggressive LDL cholesterol (LDL-C)–lowering therapy prevents cerebral events. This is why we identified our investigation of cerebral events as an exploratory analysis. Our study focused particularly on the assessment of effects of stains on atherosclerotic events. Thus, we established the secondary end point of stroke (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage) and assessed the data within that context. We believe that our findings support those of previous studies (3) that statins do not …

Journal

  • Diabetes Care

    Diabetes Care 41 (11), e145-e146, 2018-10-15

    American Diabetes Association

Citations (8)*help

See more

Details 詳細情報について

Report a problem

Back to top